Bone mineral density changes among people living with HIV who have started with TDF-containing regimen: A five-year prospective study

Win Min Han, Lalita Wattanachanya, Tanakorn Apornpong, Jureeporn Jantrapakde, Anchalee Avihingsanon, Stephen J. Kerr, Nipat Teeratakulpisarn, Tanate Jadwattanakul, Tawatchai Chaithawanarat, Patinut Buranasupkajorn, Rreshme Ramautarsing, Nittaya Phanuphak, Sarat Sunthornyothin, Kiat Ruxrungtham, Praphan Phanuphak, TNT 003.1 study team

Abstract

There are limited data regarding long-term BMD changes over time among treatment-naïve people living with HIV (PLHIV) after initiating combined antiretroviral therapy (cART) in Asia. We aimed to study bone mineral density (BMD) changes among treatment-naïve PLHIV started treatment with tenofovir disoproxil fumarate (TDF)- or non-TDF-containing regimen and HIV-uninfected controls in an Asian setting. The study was a five-year prospective study. BMD at lumbar spine (LS) (L1 to L4), total hip (TH), and femoral neck (FN) were measured by dual energy X-ray absorptiometry (DEXA) scans at baseline, months 12, 24 and 60. Multivariate logistic regression models were used to explore factors associated with mean BMD ≥5% reduction after 5 years of cART. A total of 106 PLHIV (75 and 31 started TDF- and non-TDF-containing regimen, respectively) and 66 HIV-uninfected individuals were enrolled. The mean percent changes of BMD were significantly different longitudinally between TDF and non-TDF users (p < 0.001 for LS, p = 0.006 for TH and p = 0.02 for FN). HIV-positive status and on TDF-containing regimen was independently associated with BMD loss ≥5% at month 60 (adjusted odds ratio [aOR] 7.0, 95% confidence interval [95% CI] 2.3–21.0, P = 0.001 for LS; aOR 4.9, 95%CI 1.7–14.3, P = 0.003 for TH and aOR 4.3, 95%CI 1.6–11.2, P = 0.003 for FN) compared to HIV-uninfected individuals. In a multivariate...
model for PLHIV only, TDF use (vs. non-TDF, $P = 0.005$) and pre-treatment CD4+ count 
$<350 \text{ cells/mm}^3$ (vs. $\geq 350 \text{ cells/mm}^3$, $P = 0.02$) were independently associated with 
$\geq 5\%$ BMD loss in TH at month 60. Treatment-naïve PLHIV initiating treatment with TDF-containing 
regimen have higher BMD loss in a Thai cohort. TDF use and low pre-treatment CD4 
count were independently associated with BMD loss at month 60 at TH. Earlier treatment ini-
tiation and interventions to prevent bone loss could improve skeletal health among PLHIV.

Clinicaltrials.gov: NCT01634607

Introduction

People living with HIV (PLHIV) have higher risks for decreased bone mineral density (BMD) 
and bone-related morbidities such as osteoporosis and fragility fractures compared to HIV-
negative individuals [1–7]. Several factors including sex, body mass index (BMI), vitamin D 
level, hormonal effects, smoking, alcohol drinking and HIV-related factors such as advanced 
HIV disease and low baseline CD4+ cell count may contribute to BMD loss among PLHIV [8– 
12]. Additionally, HIV-infection induced immune activation and chronic inflammation may 
alter bone formation activities by negatively affecting osteoclasts and osteoblasts functions 
[13–16]. Those activities can be measured by using bone resorption and bone formation mark-
ers such as c-telopeptide crosslink of type 1 collagen (CTX) and procollagen type 1 N-terminal 
propeptide (P1NP). We recently reported that the levels of serum P1NP and osteocalcin (OC) 
were significantly lower in treatment-naïve PLHIV (especially among those with low pre-treat-
ment CD4 cell count) than those without HIV infection in this Asian cohort [17].

Despite virological suppression with combination antiretroviral therapy (cART), treatment-
associated adverse effects are still common among PLHIV in low-middle income settings 
where treatment options are limited. Certain antiretroviral drugs such as tenofovir 
disoproxil fumarate (TDF) and some protease inhibitors (PI) have been shown to be associated 
with reduced bone mineral density (BMD) in both treatment-naïve and treatment-experi-
enced PLHIV [18–20]. Contribution of PI-based cART in reduced BMD among PLHIV may 
be mediated partly by toxic effects of concomitant TDF use. However, TDF-containing regi-
mens is still the preferred first-line cART regimen in most of the resource-limited settings even 
when combined with dolutegravir [21]. It was suggested that TDF-containing regimen has 
been associated with BMD loss [22] but there is limited data on its long-term use. A study that 
compared the long-term BMD changes between PLHIV after TDF initiation and HIV-unin-
fected controls did not find HIV- or treatment-related factors associated with BMD loss after 
24 months even though the rate of BMD decline was significantly greater in PLHIV in the first 
24 months of TDF use [23]. Moreover, data on long-term BMD changes among virologically 
suppressed PLHIV in resource-limited settings are limited, especially from Asia. We aimed to 
study the long-term BMD changes prospectively using dual X-ray absorptiometry (DEXA) 
scan among treatment-naïve PLHIV who started their treatment with either TDF-containing 
or non-TDF-containing regimen and HIV-uninfected individuals.

Methods

Study population and settings

A prospective study was conducted to evaluate BMD changes among adult Thai treatment-
aïve PLHIV after cART initiation with either TDF- or non-TDF-containing regimens from
the TNT-HIV 003 bone sub-study. HIV-uninfected healthy participants were also enrolled from the TNT-HIV 003 cohort which was established in 2012 to study the morbidity and mortality among both healthy HIV-infected and HIV-uninfected individuals from Thai Red Cross AIDS Research Centre (TRC-ARC) in Bangkok, and the Queen Savang Vadhana Memorial Hospital in Chonburi, Thailand. The main inclusion criteria for the study were age ≥ 30 years and treatment-naive for PLHIV. The decision to treat patients with or without TDF was part of the standard of care. Both HIV-infected and HIV-uninfected participants who had history of metabolic bone diseases, wasting syndrome, malignancies, comorbidities such as diabetes mellitus and hypertension, advanced opportunistic infections and active use of immunosuppressive agents, steroids or anticonvulsants were excluded from the study. The duration of the study was 60 months after the last participant was enrolled. The study participants were recruited over the period between November 2010 and May 2014. The ART treatment decisions including the timing and types of cART were based on the relevant Thai HIV guidelines during the recruitment period.

**Study measurements**

Demographic and clinical data including age, sex, BMI, waist circumference, smoking, alcohol drinking, substance use, fracture history and baseline HIV-related parameters such as CD4 + cell count, and HIV RNA levels were collected. Plasma was obtained and stored at -80°C until assayed. Estimated glomerular filtration rate (eGFR) was calculated by Chronic Kidney Disease Epidemiology Collaboration (CKD-EPI) equation. DEXA scans were also used to measure the body compositions such as total lean mass and body fat percentage.

DEXA scans were employed to measure BMD at the lumbar spine (LS) (L1 to L4), total hip (TH), and femoral neck (FN) by using a QDR 4500 bone densitometer (Hologic, Inc., Bedford, MA) at baseline, months 12, 24 and 60. BMD T- and Z-scores were analyzed using Asian population reference data supplied by the manufacturer. Serum calcium, phosphorus (ICMA; intact PTH assays Roche Elecsys®) and serum 25-hydroxyvitamin D (25(OH)D) levels (CLIA; Diasorin LIAISON®) were measured at baseline. Baseline urine phosphate and creatinine levels were also assessed to calculate the fractional excretion of phosphate (FEPO4) by using the formula: [PO4 (Urine) * Creatinine (Serum)] / [PO4 (Serum) * Creatinine (Urine)] * 100% [24, 25]. Additionally, bone turnover markers, P1NP, OC and CTX, were measured only at baseline by using a chemiluminescence immunoassay (Roche Diagnostics, Mannheim, Germany).

**Definitions of the study endpoints**

The prevalence of clinical status of reduced BMD was measured by osteoporosis and osteopenia events among study participants. Osteoporosis and osteopenia were defined as a T-score ≤ -2.5 standard deviation (SD) and between -1 and -2.5 SD below the young adult mean value [26], respectively. We also reported Z-score from the classification system of the International Society for Clinical Densitometry (ISCD), which defines a Z-score ≤ -2.0 SD as “below the expected range for age”. The study’s main outcome for the modelling analyses was defined as ≥ 5% reduction in the mean BMD (grams per square centimeter, g/cm²) after 60 months of cART at each anatomical site.

**Statistical analysis**

Demographic data and baseline HIV-related parameters, levels of bone markers, BMD at different sites, calcium and vitamin D status were described descriptively as median (IQR), mean (SD), or number (percentage). Comparisons between the study groups (HIV-infected vs. HIV-uninfected and TDF-containing regimen vs. non-TDF-containing regimen) were done by
using t-test or Mann-Whitney U tests for continuous variables and Chi-square or Fisher’s Exact tests for categorical variables. Relative BMD changes of the early phase (month 0 to month 24) and late phase (month 0 to month 60) of cART initiation were also compared for each anatomical site. Univariate and multivariate logistic regression models were employed to evaluate factors associated with reduced BMD ≥ 5% at month 60 (compared to baseline) at each site. The scans from PLHIV on TDF-containing regimen were compared to non-TDF containing regimen. Age, sex, BMI and all other variables with p-values < 0.15 were adjusted in multivariate regression models. Separate models were also employed to evaluate HIV-related variables associated with reduction of mean BMD ≥ 5% at month 60 among PLHIV only. A p-value less than 0.05 was considered significant. Sensitivity analyses were done by decreasing the cut off of BMD reduction at month 60 from ≥ 5% to ≥ 3% for all three anatomical sites. All analyses were done using STATA version 15.1 (STATA Corp LLC, College Station, TX).

Ethical consideration
The study was reviewed and approved by the Institutional Review Board of the Faculty of Medicine, Chulalongkorn University, Bangkok, Thailand. All HIV-infected and HIV-uninfected participants in the study provided written informed consents.

Results
Participants’ characteristics
A total of 106 PLHIV (75 started with TDF-containing regimen and 31 started with non-TDF-containing regimen) and 66 HIV-uninfected individuals were included in the study analyses. Demographics and baseline characteristics of participants were stratified by either HIV status or by the use of TDF as displayed in Table 1. Median age of all participants was 38.3 (interquartile range [IQR] 35.3–44.0) years. In our study, PLHIV were relatively younger than HIV-uninfected individuals (37.2 vs. 41.1 years, P < 0.001). Both PLHIV and HIV-uninfected individuals had comparable body compositions which were determined by total lean mass and body fat percentages from DEXA scans. The number of participants still in the study at month 60 for the TDF group was 53/101 (52%), and for the non-TDF group, it was 19/49 (39%). Therefore, non-TDF group had a higher rate of loss to follow-up (LTFU) at month 60 (30/49, 61%). The two groups, TDF and non-TDF users, had similar median age at study entry (37.0 vs. 38.2 years, P = 0.8). At baseline, the participants from both groups did not have a proteinuria event. Sixty-eight percent of the participants started treatment with TDF, lamivudine and emtricitabine or efavirenz (TDF/3TC(or)FTC/EFV) as their initial regimen. PI use was only 3.77% among the study participants. There were no differences in BMI at baseline between the two treatment groups (P = 0.56). All participants from different treatment groups had similar total body fat percentages (27 vs. 25%, P = 0.9) and total lean mass (41.5 vs. 42.2 kg, P = 0.8) at baseline.

Baseline levels of serum calcium, phosphate, 25(OH)D, and bone turnover markers are presented in Table 1. There were no significant differences in baseline levels of 25(OH)D (p = 0.76), OC (p = 0.58), CTX (p = 0.68) and P1NP (p = 0.57) between those starting treatment with TDF- or non-TDF-containing regimens. The prevalence of abnormal vitamin D level (insufficiency or deficiency) at baseline was similar in both groups. There were also no differences in serum calcium and phosphate levels between the groups.

However, ARV-naïve PLHIV had lower pre-treatment bone turnover markers (OC, CTX, and P1NP) than HIV-uninfected controls at baseline. Of note, PLHIV had higher vitamin D level than HIV-uninfected individuals at baseline (24.1 IQR, 18.6–29.7 vs. 31.2 IQR, 26.8–36.5
Table 1. Baseline characteristics of the study participants.

| Baseline covariates | Total (n = 172) | HIV-uninfected (n = 66) | HIV-infected (n = 106) | P-value | TDF-containing regimen (n = 75) | Non-TDF containing regimen (n = 31) | P-value |
|---------------------|----------------|-------------------------|------------------------|---------|-------------------------------|-----------------------------------|---------|
| **Sex**             |                |                         |                        |         |                               |                                   |         |
| Male                | 88 (51.16)     | 29 (43.94)              | 59 (55.66)             | 0.14    | 42 (56.00)                    | 17 (54.84)                        | 0.9     |
| Female              | 84 (48.84)     | 37 (56.06)              | 47 (44.34)             |         | 33 (44.00)                    | 14 (45.16)                        |         |
| **Age, median (IQR)** | 38.3 (35.3–44.0) | 41.1 (37.2–46.3) | 37.2 (34.5–41.5) | 0.0001 | 37.0 (34.5–41.9) | 38.2 (34.1–40.9) | 0.87 |
| **BMI (kg/m²)**     | 22.7 (21.0–24.9) | 23.8 (21.2–25.8) | 22.5 (20.9–24.7) | 0.11    | 22.5 (21.0–24.4) | 22.5 (20.8–25.9) | 0.56 |
| Abnormal waist*, n (%) | 62 (36.05)     | 31 (46.97)              | 31 (29.25)             | 0.02    | 18 (24)                       | 13 (41.94)                        | 0.07    |
| Dyslipidemia       | 69/171 (40.4)  | 41/66 (62.1)            | 28/105 (26.7)          | <0.001  | 20/74 (27)                    | 8/31 (25.8)                       | 0.90    |
| Fracture history   | 18 (23.1)      | 5 (27.8)                | 13 (21.7)              | 0.75    | 9/42 (21.4)                   | 4/18 (22.2)                       | 1.00    |
| eGFR (mL/min/1.73m²)| 89.4 (75.8–105.4) | 85.3 (75.2–108.1) | 92.6 (77.4–104.2) | 0.83    | 88.2 (77.5–103.3) | 96.1 (75.0–108.1) | 0.52    |
| 25 (OH) D (ng/mL)  | 28.9 (22.9–34.3) | 24.1 (18.6–29.7) | 31.2 (26.8–36.5) | <0.001  | 31.2 (26.4–36.2) | 30.6 (27.8–37.7) | 0.76    |
| 25 (OH) D, ng/mL, n (%) |              |                        |                       | <0.001  |                               |                                   |         |
| <20 (deficiency)   | 26 (16.1)      | 20 (30.8)               | 6 (6.2)                |         | 6 (8.6)                       | 0 (0)                             |         |
| 20–30 (insufficiency) | 68 (42.0)     | 31 (47.7)               | 37 (38.1)              |         | 24 (34.3)                     | 13 (48.2)                         |         |
| 30–100 (sufficiency) | 68 (42.0)      | 14 (21.5)               | 54 (55.7)              |         | 40 (57.1)                     | 14 (51.9)                         |         |
| **HIV-related variables** |            |                         |                        |         |                               |                                   |         |
| Baseline CD4 count (cells/mm³) | 274 (173–379) | 285 (164–412) | 253 (175–312) | 0.22    |                               |                                   |         |
| Baseline HIV-RNA level (log₁₀ copies/mL) | 4.8 (4.3–5.2) | 4.8 (4.2–5.2) | 4.7 (4.4–5.3) | 0.61    |                               |                                   |         |
| CDC staging        |                |                         |                        |         |                               |                                   | 0.51    |
| A                   | 76 (71.70)     | 56 (74.67)              | 20 (64.52)             |         |                               |                                   |         |
| B                   | 27 (25.47)     | 17 (22.67)              | 10 (32.26)             |         |                               |                                   |         |
| C                   | 3 (2.83)       | 2 (2.67)                | 1 (3.23)               |         |                               |                                   |         |
| Protease inhibitors use | 4 (3.77)       | 1 (1.33)                | 3 (9.68)               | 0.07    |                               |                                   |         |
| Bone markers        |                |                         |                        |         |                               |                                   |         |
| Serum calcium, mg/dL | 9.5 (9.3–9.7)  | 9.6 (9.3–9.8)           | 9.4 (9.1–9.7)          | 0.005   | 9.4 (9.1–9.7)                 | 9.4 (9.2–9.7)                     | 0.55    |
| Serum phosphate, mg/dL | 3.8 (3.5–4.2) | 3.9 (3.6–4.2)          | 3.8 (3.5–4.2)          | 0.71    | 3.8 (3.5–4.2)                 | 3.7 (3.5–4.2)                     | 0.49    |
| OC, l ng/mL         | 13.2 (10.0–17.9) | 15.9 (13.1–20.2) | 11.0 (9.0–15.2) | <0.001  | 11.2 (9.7–14.9) | 10.5 (8.7–17.4) | 0.58    |
| CTX, ng/mL          | 0.3 (0.2–0.4)  | 0.3 (0.2–0.4)           | 0.2 (0.1–0.3)          | 0.0007  | 0.2 (0.1–0.3)                 | 0.2 (0.1–0.3)                     | 0.68    |
| P1NP, ng/mL         | 38.2 (29.8–50.9) | 44.7 (36.6–55.1) | 33.1 (27.4–42.6) | 0.0001  | 32.9 (27.5–41.7) | 34.6 (26.0–48.7) | 0.57    |
| **BMD at lumbar spine** |                    |                         |                        |         |                               |                                   |         |
| BMD (g/cm²)         | 0.98 (0.12)    | 0.97 (0.12)             | 0.99 (0.12)            | 0.22    | 1.00 (0.12)                   | 0.99 (0.11)                       | 0.68    |
| T-score, mean (SD)  | -0.26 (1.02)   | -0.37 (1.04)            | -0.19 (1.00)           | 0.27    | -0.18 (1.04)                  | -0.24 (0.92)                      | 0.76    |
| Z-score, mean (SD)  | -0.02 (0.90)   | -0.05 (0.89)            | 0.00 (0.91)            | 0.70    | 0.03 (0.93)                   | -0.06 (0.87)                      | 0.66    |
| **BMD at hip**      |                    |                         |                        |         |                               |                                   |         |
| BMD (g/cm²)         | 0.92 (0.13)    | 0.90 (0.12)             | 0.93 (0.13)            | 0.13    | 0.92 (0.13)                   | 0.95 (0.12)                       | 0.37    |
| T-score, mean (SD)  | 0.22 (1.02)    | 0.11 (0.95)             | 0.29 (1.06)            | 0.24    | 0.23 (1.08)                   | 0.45 (1.01)                       | 0.32    |
| Z-score, mean (SD)  | 0.37 (1.01)    | 0.30 (0.94)             | 0.41 (1.05)            | 0.48    | 0.35 (1.06)                   | 0.56 (1.02)                       | 0.35    |
| **BMD at femoral neck** |                |                         |                        |         |                               |                                   |         |
| BMD (g/cm²)         | 0.79 (0.12)    | 0.77 (0.11)             | 0.80 (0.13)            | 0.17    | 0.79 (0.13)                   | 0.82 (0.13)                       | 0.35    |
| T-score, mean (SD)  | -0.31 (1.04)   | -0.46 (0.94)            | -0.22 (1.09)           | 0.18    | -0.28 (1.09)                  | -0.05 (1.09)                      | 0.31    |

(Continued)
Percentage of mean BMD changes from baseline to months 12, 24 and 60 in PLHIV on TDF-containing versus non-TDF-containing regimen

The mean percentage changes of BMD at different anatomical sites at months 12, 24 and 60 are shown in Fig 1. The mean percentage changes of BMD for TDF and non-TDF users in LS (Fig 1A) were -4.7% versus -0.8% at month 12, -4.7% vs. -2.8% at month 24, and -5.4% vs. -0.9% at month 60, respectively (p < 0.001). For TH (Fig 1B), percentage changes in BMD for TDF and non-TDF groups were -3.6% vs. -1.9% at month 12, -3.2% vs. -1.8% at month 24 and -4% vs. 0.1% at month 60, respectively (p = 0.006). The changes were also significant between the two groups for FN over the study period, p = 0.02 (Fig 1C). For longitudinal comparison over 60 months of treatment, TDF users had significantly higher mean BMD loss of -2.08% (95% CI, -2.91 to -1.25), p < 0.001) in LS, -1.37% (95% CI, -2.35 to -0.39, p = 0.006) in TH, and -1.06 (95% CI, -1.97 to -0.16), p = 0.02) in FN, than non-TDF users.

We also compared the BMD changes from baseline to month 12 versus months 12 to 24 (Table 2). Changes in BMD from baseline to month 12 among TDF users were significantly higher than the changes in months 12 to 24 [-3.9% (95% CI, -5.7 to -1.4) vs. -0.1% (95% CI, -2.0 to 0.6), p<0.001 for LS, -4.2% (-6.9 to -2.4) vs. -0.4% (-3.0 to 1.2), p = 0.002 for TH and -4.6% (-7.9 to -2.7) vs. 0% (-2.9 to 2.1), p = 0.017 for FN]. Of note, the BMD changes among TDF users from baseline to month 24 were statistically higher than the changes from months 24 to 60 at LS, (-3.58% vs. 0%, p = 0.014), TH (-5.5% vs. -0.2%, p = 0.008) and FN (-6.1 vs. -0.5%, p = 0.002) (Table 2).

Prevalence of combined osteopenia and osteoporosis at baseline and month 60

Overall, there were some participants who had osteoporosis in our study over the follow-up years. At baseline, the prevalence of combined osteoporosis and osteopenia in TH, FN and LS was 0%, 16% and 21% among treatment-naïve PLHIV who initiated treatment with non-TDF-containing regimen and 15%, 32% and 19% among those who started treatment with TDF-containing regimen, respectively. The prevalence of combined osteoporosis or osteopenia was then increased to 0%, 32% and 26% in in TH, FN and LS among non-TDF users and 20%, 55% and 36% among TDF users after 60 months of cART (Fig 2). There were no significant differences in the prevalence of combined osteoporosis and osteopenia between TDF users and HIV-uninfected individuals at each site at 60 months. In addition, there were no differences in the proportions of participants with Z-scores ≤−2.0 SD between the two treatment arms of each anatomical site at any time point.
Factors associated with ≥ 5% BMD loss at month 60 in both HIV-infected and HIV-uninfected individuals

The prevalence of BMD loss ≥ 5% among both HIV-infected and HIV-uninfected participants was 35%, 28% and 42% at in TH, FN and LS, respectively. The logistic regression models were employed to evaluate the variables associated with the outcomes of ≥ 5% reduction in BMD from baseline to month 60. In the multivariate models, when we included both PLHIV and HIV-uninfected individuals, we found that the HIV-positive status and TDF-containing regimen were independently associated with ≥ 5% decrease in BMD at month 60 for all sites (adjusted odds ratio [aOR] 7.0, 95% confidence interval [95% CI] 2.3–21.0, P = 0.001 for LS; aOR 4.9, 95% CI 1.7–14.3, P = 0.003 for TH and; aOR 4.3, 95% CI 1.6–11.2, P = 0.003 for FN) compared to HIV-uninfected individuals after adjusting for age, sex and BMI (Table 3). The associations remained significant after controlling for bone turnover markers (CTX and P1NP) and FEPO4 at baseline in the multivariate analyses. In addition, women were more likely to have BMD loss at LS (aOR 4.1, 95% CI 1.7–10.2, P = 0.02) compared to their counterparts. From the model analyses, we did not find the associations of bone turnover markers, use

Table 2. Comparison of relative BMD changes between the early phase (month 0 to month 24) and late phase (month 0 to month 60) of treatment.

| Relative BMD changes | Month 0 –month 12 | Month 0 –month 24 | P-value | Month 0 –month 24 | Month 0 –month 48 | P-value |
|----------------------|-------------------|------------------|---------|------------------|------------------|---------|
|                      | Median (95% CI)   | Median (95% CI)  |         | Median (95% CI)  | Median (95% CI)  |         |
| Lumbar Spine         |                   |                  |         |                  |                  |         |
| TDF                  | -3.9 (-5.7 to -1.4)| -0.1 (-2 to 0.6) | <0.001  | -3.6 (-6.4 to -1.0)| 0.0 (-2.1 to 2.8)| 0.014   |
| Non-TDF              | -1.3 (-3.5 to -0.7)| -0.1 (-2.1 to 2.2)| 0.37     | -0.9 (-2.2 to 0.89)| -0.2 (-2.0 to 1.6)| 0.395   |
| Total Hip            |                   |                  |         |                  |                  |         |
| TDF                  | -4.2 (-6.9 to -2.4)| -0.4 (-3.0 to 1.2)| 0.002   | -5.5 (-7.7 to -3.5)| -0.2 (-4.0 to 3.3)| 0.008   |
| Non-TDF              | -2.7 (-3.3 to 0.3)| 0.1 (-0.6 to 1.5)| 0.63     | -0.2 (-3.0 to 6.6)| 0.5 (-6.5 to 2.6)| 0.65    |
| Femoral Neck         |                   |                  |         |                  |                  |         |
| TDF                  | -4.6 (-7.9 to -2.7)| 0.00 (-2.9 to 2.1)| 0.017   | -6.1 (-8.9 to -3.7)| -0.5 (-2.5 to 1.8)| 0.002   |
| Non-TDF              | -3.8 (-8.4 to 2.0)| 1.4 (-2.0 to 2.4)| 0.08     | -2.5 (-6.0 to -0.9)| -2.8 (-3.6 to -1.2)| 0.45    |

https://doi.org/10.1371/journal.pone.0230368.t002
Factors associated with $\geq 5\%$ BMD loss at month 60 among HIV–infected individuals

The prevalence of BMD loss $\geq 5\%$ among TDF users was higher than non-TDF users (49% vs. 26%, $p = 0.086$ in LS, 43% vs. 11%, $p = 0.01$ in TH and 55% vs. 37%, $p = 0.18$ in FN, respectively). In separate multivariate models for PLHIV only, we found that TDF use (vs. non-TDF, aOR 11.7, 95% CI 2.1–64, $P = 0.005$) and baseline CD4+ cell count $< 350$ cells/mm$^3$ (vs. $\geq 350$ cells/mm$^3$, aOR 7.1, 95% CI 1.3–38.8, $P = 0.02$) were independently associated with $\geq 5\%$ BMD loss (Table 3) at TH but not at the other sites at month 60 after adjusting for age, BMI, baseline CD4 count, HIV RNA level and other significant cofounders from the univariate model. However, women were more likely to have BMD loss than men at LS (aOR 3.0, 95% CI 1.0–8.8, $P = 0.05$). In other models, we did not find the associations of HIV RNA level, CDC staging, body fat and lean mass, serum calcium, 25(OH)D levels and bone turnover markers, with BMD loss at month 60.
Sensitivity analysis

A sensitivity analysis using month 60 BMD loss cut off as ≥ 3% was performed to test the robustness of our findings. The significant associations of HIV-infected status and TDF use remained unchanged at all three anatomical sites. However, the association of baseline CD4 cell count and ≥3% BMD reduction at TH was lost in the sensitivity analysis.

Discussion

There are limited data regarding long-term BMD changes over time among treatment-naïve PLHIV after initiating cART in Asia. In this prospective study, we determined the long-term BMD changes among HIV-uninfected individuals and treatment-naïve PLHIV initiating either TDF- or non-TDF-containing regimens. We found that TDF users were likely to have greater BMD loss than non-TDF users at month 60. Additionally, our findings suggest that initial cART regimen containing TDF had the greatest BMD loss in the first 12 months of its use. From the multivariate models, including both PLHIV and negative controls, we found that those started with TDF-containing regimen (compared to HIV-uninfected participants) was independently associated with ≥5% BMD loss at month 60 at all three anatomical sites studied. Among the models in this study, only PLHIV who started treatment with TDF-containing

---

**Table 3. Multivariate analyses for ≥5% BMD loss at month 60 at the lumbar spine, total hip and femoral neck.**

| Baseline variates for both PLHIV and HIV-uninfected participants | BMD ≥5% reduction at lumbar spine' (prevalence, 35%) | BMD ≥5% reduction at total hip" (prevalence, 28%) | BMD ≥5% reduction at femoral neck" (prevalence, 42%) |
|---------------------------------------------------------------|--------------------------------|--------------------------------|--------------------------------|
|                                                              | aOR (95% CI) | P-value | aOR (95% CI) | P-value | aOR (95% CI) | P-value |
| **Age (vs. <40 years)**                                      |               |         |               |         |               |         |
| ≥40                                                          | 1.5 (0.6–3.7) | 0.4     | 1.2 (0.5–3.1) | 0.7     | 1.7 (0.7–3.9) | 0.2     |
| **Female (vs. male)**                                        | 4.1 (1.7–10.2) | 0.02    | 1.9 (0.8–4.6) | 0.2     | 1.2 (0.5–2.6) | 0.6     |
| **BMI (vs. <25 kg/m²)**                                      |               |         |               |         |               |         |
| ≥25                                                          | 1.7 (0.6–4.5) | 0.3     | 1.4 (0.5–3.8) | 0.6     | 2.2 (0.9–5.5) | 0.1     |
| **HIV status (vs. HIV negative)**                            |               |         |               |         |               |         |
| HIV started with TDF                                         | 7.0 (2.3–21.0) | 0.001   | 4.9 (1.7–14.3) | 0.003   | 4.3 (1.6–11.2) | 0.003   |
| HIV started with non-TDF                                     | 2.1 (0.5–8.1) | 0.3     | 0.7 (0.1–3.7) | 0.7     | 1.7 (0.5–5.9) | 0.4     |
| **Baseline variates for PLHIV only**                        |               |         |               |         |               |         |
| **Age (vs. <40 years)**                                      |               |         |               |         |               |         |
| ≥40                                                          | 1.2 (0.4–3.6) | 0.8     | 1.0 (0.3–3.4) | 1.0     | 2.4 (0.8–7.2) | 0.1     |
| **Female (vs. male)**                                        | 3.0 (1.0–8.8) | 0.05    | 2.1 (0.7–6.7) | 0.2     | 1.1 (0.4–3.2) | 0.8     |
| **BMI (vs. <25 kg/m²)**                                      |               |         |               |         |               |         |
| ≥25                                                          | 3.2 (0.8–13.1) | 0.1     | 3.1 (0.7–14.5) | 0.1     | 2.9 (0.7–11.3) | 0.1     |
| **cART regimen (vs. non-TDF)**                               |               |         |               |         |               |         |
| TDF                                                          | 3.1 (0.9–11.1) | 0.1     | 11.7 (2.1–64) | 0.005   | 2.8 (0.8–9.2) | 0.1     |
| **Baseline CD4+ cell count (vs. ≥350 cells/mm3)**            |               |         |               |         |               |         |
| <350 cells/mm3                                               | 1.9 (0.5–7.1) | 0.3     | 7.1 (1.3–38.8) | 0.02    | 2.3 (0.7–7.9) | 0.2     |
| **Baseline HIV RNA level (log_{10} copies/mL)**             |               |         |               |         |               |         |
| <2 copies/mL                                                 | 2.1 (1.0–4.5) | 0.06    | 0.8 (0.4–1.9) | 0.7     | 1.2 (0.6–2.5) | 0.5     |

* Multivariate models with both PLHIV and HIV-uninfected controls were adjusted for age, sex, BMI and HIV status.

** Multivariate models with only PLHIV that were adjusted for age, sex, BMI, cART regimen (TDF vs. non-TDF), baseline CD4 count and baseline HIV-RNA level.

https://doi.org/10.1371/journal.pone.0230368.t003

**Sensitivity analysis**

A sensitivity analysis using month 60 BMD loss cut off as ≥ 3% was performed to test the robustness of our findings. The significant associations of HIV-infected status and TDF use remained unchanged at all three anatomical sites. However, the association of baseline CD4 cell count and ≥ 3% BMD reduction at TH was lost in the sensitivity analysis.

**Discussion**

There are limited data regarding long-term BMD changes over time among treatment-naïve PLHIV after initiating cART in Asia. In this prospective study, we determined the long-term BMD changes among HIV-uninfected individuals and treatment-naïve PLHIV initiating either TDF- or non-TDF-containing regimens. We found that TDF users were likely to have greater BMD loss than non-TDF users at month 60. Additionally, our findings suggest that initial cART regimen containing TDF had the greatest BMD loss in the first 12 months of its use. From the multivariate models, including both PLHIV and negative controls, we found that those started with TDF-containing regimen (compared to HIV-uninfected participants) was independently associated with ≥5% BMD loss at month 60 at all three anatomical sites studied. Among the models in this study, only PLHIV who started treatment with TDF-containing
regimen and the female sex were independently associated with BMD loss at month 60 at LS (but not at TH or FN) after potential confounders were controlled.

The results of BMD changes of our study were in line with previous reports that the BMD loss among PLHIV was associated with TDF use and low pre-treatment CD4+ cell count [12, 27, 28]. Previous evidences showed that among treatment naïve HIV participants whose initial regimen was TDF-based regimen had nearly 1–3% BMD loss at 12 to 36 months after starting treatment compared to those who had non-TDF containing regimen [18, 20, 27, 29–31]. Our data supported those previous evidences that BMD loss was higher in the first 12 months and stabilized after 24 months of using TDF-containing cART as the initial regimen. However, few studies have evaluated long-term BMD changes with TDF use. In our cohort, we found that PLHIV on TDF-containing regimen was an independent risk factor for BMD loss of ≥ 5% from baseline to 60 months at total hip after potential confounders were controlled in the analyses. Furthermore, we also found that there was an independent association of low pre-treatment CD4+ cell count with BMD loss at total hip. The association of low baseline CD4+ cell count and BMD loss suggests that the immune system could have potential roles in the changes of the metabolism of the skeletal tissues.

In our study, women living with HIV had higher risks for BMD loss at month 60 at the LS (but not at TH or FN). Given that women have higher skeletal fracture risks than men, this is an important implication that HIV-infected women should be screened for osteoporosis or osteopenia regularly. Interventions such as treatment with bisphosphate and switching to other bone-friendly cART regimen with less BMD toxicities should be considered for those found to have osteoporosis and osteopenia.

Furthermore, previous studies have explored the association of body weight with BMD loss among PLHIV [7, 32]. However, we did not observe the associations of BMI or waist circumference with BMD loss at month 60 at any anatomical sites. In addition, our study did not find the association of HIV RNA level and BMD loss. This could possibly be explained by the reason that our study participants had successful treatment or that the effects of ARV (for instance, TDF) overwhelmed the viremia effect. We also failed to observe the relationship of advanced HIV disease with BMD loss. It might be because our participants were relatively healthy at cART initiation since individuals with wasting syndrome or opportunistic infections were excluded at the screening visit.

HIV-induced chronic immune activation could affect bone metabolism and hence increase bone loss. In this study, we did not find associations of baseline urinary phosphate wasting and bone turnover markers with BMD change in the multivariate models. However, several reports have suggested the predictive role of baseline bone turnover markers for BMD loss among TDF users [16] or BMD gain after switching from TDF [33]. For example, one study evaluated BMD changes after switching from TDF to tenofovir alafenamide (TAF) among PLHIV with low BMD; TDF-treated individuals with high baseline PN1P levels who switched to TAF had increased BMD after 24 months on TAF [33]. Moreover, a number of studies have suggested that there is a relationship between BMD loss and low serum 25(OH)D levels. In this study, we did not find such an association. It could be explained by the fact that most of the study participants were healthy and had low rate of vitamin D deficiency at baseline in our cohort. However, PLHIV started with TDF-containing regimen had greater BMD loss than uninfected individuals although serum 25(OH)D levels were higher among all PLHIV at baseline. The prevalence of osteoporosis was low. A possible explanation for this is that our study participants had few traditional risk factors for BMD loss and the young median age at cART initiation. Another plausible explanation is that the study used the outcome as BMD loss at month 60 with the cut off of 5% and this could overestimate bone loss in the cohort. In a systematic review of cART in the early years showed that treatment-naïve individuals on TDF containing
regimen had 1–3% BMD loss at 12 to 24 months. When a 3% cut off was used for the sensitivity analysis, we found a significant association between TDF use and BMD loss at month 60.

Several limitations of our study should be acknowledged. First, there were high rates of LTFU among the study participants, especially among PLHIV from the non-TDF group. Therefore, the risk factors identified in our results should be interpreted cautiously and further studies with a larger sample size may be needed to confirm these findings. Second, the measurements of the bone markers were only done at baseline visits. Third, the treatment arm (TDF or non-TDF) was not randomly assigned to treatment-naïve HIV-infected participants, and hence, the selection bias could not be totally excluded. However, all HIV-infected and healthy HIV-uninfected participants enrolled in the study did not have comorbidities such as diabetes, hypertension and bone metabolic diseases. Moreover, our study is the first Asian cohort that assessed the BMD loss in treatment-naïve HIV-infected individuals using TDF- or non TDF containing regimens over a 5-years period. DEXA scans were done at baseline, months 12, 24 and 60. These data were analyzed and compared to the results from HIV-uninfected controls which had equal numbers of men and women as the PLHIV group.

Conclusion

We found that treatment-naïve HIV-infected individuals who started their treatment with TDF-containing regimen continued to have BMD loss at 5 years even though the rate was slower after 24 months of treatment. Compared with HIV-uninfected individuals and PLHIV on non-TDF-containing regimen, TDF users were more likely to have BMD loss at all three anatomical sites. In addition, lower pre-treatment CD4 count was associated with BMD loss at month 60 at total hip. Therefore, early HIV diagnosis and rapid cART initiation or interventions to prevent BMD loss may improve the bone health among PLHIV with long-term virological suppression.

Supporting information

S1 Checklist. Strobe statement—Checklist of items that should be included in reports of cohort studies.

(DOC)

Acknowledgments

We are indebted to all participants for their time in this study. We also would like to thank all of the staff from the Thai Red Cross AIDS Research Centre, HIV-NAT and Queen Savang Vadhana Memorial Hospital for their strong commitment to the study and hard work.

TNT 003.1 study team

HIV-NAT, the Thai Red Cross AIDS Research Centre, Bangkok, Thailand: Praphan Phanuphak, Anchalee Avihingsanon, Kiat Ruxrungtham, Jintanat Ananworanich, Chintana Chaturawit, Reshmie Ramautarsing, Nittaya Phanuphak, Nipat Teeratakulpisarn, Tanakorn Apornpong, Patinut Buranasupkajorn, Lalita Wattanachanya, Sarat Sunthornyothin

Queen Savang Vadhana Memorial Hospital: Tanate Jadwattanakul, Pornpen Mathajittiphun

Author Contributions

Conceptualization: Lalita Wattanachanya, Tanakorn Apornpong, Anchalee Avihingsanon, Patinut Buranasupkajorn, Nittaya Phanuphak, Sarat Sunthornyothin, Kiat Ruxrungtham, Praphan Phanuphak.
Data curation: Win Min Han, Lalita Wattanachanya, Tanakorn Apornpong.
Formal analysis: Win Min Han, Lalita Wattanachanya, Tanakorn Apornpong.
Funding acquisition: Lalita Wattanachanya.
Investigation: Anchalee Avihingsanon, Nipat Teeratakulpisarn, Tanate Jadwattanakul.
Methodology: Lalita Wattanachanya, Anchalee Avihingsanon, Patinut Buranasupkajorn, Nittaya Phanuphak, Sarat Sunthornyothin, Kiat Ruxrungtham, Praphan Phanuphak.
Project administration: Lalita Wattanachanya, Anchalee Avihingsanon.
Supervision: Anchalee Avihingsanon.
Writing – original draft: Win Min Han.
Writing – review & editing: Win Min Han, Lalita Wattanachanya, Tanakorn Apornpong, Jurjeeporn Jantrapakde, Anchalee Avihingsanon, Stephen J. Kerr, Nipat Teeratakulpisarn, Tanate Jadwattanakul, Tawatchai Chaiwatanarat, Patinut Buranasupkajorn, Reshmie Ramautarsing, Nittaya Phanuphak, Sarat Sunthornyothin, Kiat Ruxrungtham, Praphan Phanuphak.

References
1. Brown TT, Qaqish RB. Antiretroviral therapy and the prevalence of osteopenia and osteoporosis: a meta-analytic review. AIDS. 2006; 20(17):2165–74. https://doi.org/10.1097/QAD.0b013e32801022eb PMID: 17086056
2. Triant VA, Brown TT, Lee H, Grinspoon SK. Fracture prevalence among human immunodeficiency virus (HIV)-infected versus non-HIV-infected patients in a large U.S. healthcare system. The Journal of clinical endocrinology and metabolism. 2008; 93(9):3499–504. https://doi.org/10.1210/jc.2008-0828 PMID: 18593764
3. Shiau S, Broun EC, Arpadi SM, Yin MT. Incident fractures in HIV-infected individuals: a systematic review and meta-analysis. AIDS. 2013; 27(12):1949–57. https://doi.org/10.1097/QAD.0b013e328361d241 PMID: 24126140
4. Guerri-Fernandez R, Vestergaard P, Carbonell C, Knobel H, Aviles FF, Castro AS, et al. HIV infection is strongly associated with hip fracture risk, independently of age, gender, and comorbidities: a population-based cohort study. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2013; 29(6):1259–63.
5. Battalora LA, Young B, Overton ET. Bones, Fractures, Antiretroviral Therapy and HIV. Curr Infect Dis Rep. 2014; 16(2):393-. https://doi.org/10.1007/s11908-014-0393-1 PMID: 24535243
6. Grant PM, Kitch D, McComsey GA, Collier AC, Koletar SL, Erlandson KM, et al. Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. J Infect Dis. 2016; 214(4):607–11. https://doi.org/10.1093/infdis/jiw204 PMID: 27330053
7. Kooij KW, Wit FW, Bisschop PH, Schouten J, Stolte IG, Prins M, et al. Low bone mineral density in patients with well-suppressed HIV infection: association with body weight, smoking, and prior advanced HIV disease. J Infect Dis. 2015; 211(4):539–48. https://doi.org/10.1093/infdis/jiu499 PMID: 25180239
8. Amorosa V, Tebas P. Bone disease and HIV infection. Clin Infect Dis. 2006; 42(1):108–14. https://doi.org/10.1086/498511 PMID: 16323100
9. Arnsten JH, Freeman R, Howard AA, Floris-Moore M, Santoro N, Schoenbaum EE. HIV infection and bone mineral density in middle-aged women. Clin Infect Dis. 2006; 42(7):1014–20. https://doi.org/10.1086/501015 PMID: 16511769
10. Compston JE, Flahive J, Hosmer DW, Watts NB, Siris ES, Silverman S, et al. Relationship of weight, height, and body mass index with fracture risk at different sites in postmenopausal women: the Global Longitudinal study of Osteoporosis in Women (GLOW). Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 2014; 29(2):487–93.
11. McComsey GA, Tebas P, Shane E, Yin MT, Overton ET, Huang JS, et al. Bone disease in HIV infection: a practical review and recommendations for HIV care providers. Clin Infect Dis. 2010; 51(8):937–46. https://doi.org/10.1086/656412 PMID: 20839988
12. Grant PM, Kitch D, McComsey GA, Dube MP, Haubrich R, Huang J, et al. Low baseline CD4+ count is associated with greater bone mineral density loss after antiretroviral therapy initiation. Clin Infect Dis. 2013; 57(10):1483–8. https://doi.org/10.1093/cid/cit538 PMID: 23943825

13. Mondy K, Yarasheski K, Powderly WG, Whyte M, Claxton S, DeMarco D, et al. Longitudinal evolution of bone mineral density and bone markers in human immunodeficiency virus-infected individuals. Clin Infect Dis. 2003; 36(4):482–90. https://doi.org/10.1086/367569 PMID: 12567307

14. Hileman CO, Labbate DE, Storer NJ, Tangpricha V, McComsey GA. Changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. J Acquir Immune Defic Syndr. 2009; 51(5):554–61. https://doi.org/10.1097/QAI.0b013e3181adc44 PMID: 19512937

15. De Menezes EG, Machado AA, Barbosa F Jr., da Paula FJ, Navarro AM. Bone metabolism dysfunction mediated by the increase of proinflammatory cytokines in chronic HIV infection. Journal of bone and mineral metabolism. 2017; 35(2):234–42. https://doi.org/10.1007/s00774-016-0749-8 PMID: 27026434

16. Vlot MC, Grijsen ML, Prins JM, de Jonge R, den Heijer M, et al. Effect of antiretroviral therapy on bone turnover and bone mineral density in men with primary HIV-1 infection. PLoS One. 2018; 13(3):e0193679. https://doi.org/10.1371/journal.pone.0193679 PMID: 29522570

17. Watanachanya L, Jantraphand J, Avihingsanon A, Ramautarsing R, Kerr S, Trachunthong D, et al. Antiretroviral-naive HIV-infected patients had lower bone formation markers than HIV-uninfected adults. AIDS care. 2019:1–10.

18. Stellbrink HJ, Orkin C, Arribas JR, Compston J, Gerstoft J, Van Wijngaarden E, et al. Comparison of changes in bone density and turnover with abacavir-lamivudine versus tenofovir-emtricitabine in HIV-infected adults: 48-week results from the ASSERT study. Clin Infect Dis. 2010; 51(8):963–72. https://doi.org/10.1086/656417 PMID: 20828304

19. Duivier C, Kolta S, Assoumou L, Ghosn J, Rozenberg S, Murphy RL, et al. Greater decrease in bone mineral density with protease inhibitor regimens compared with nonnucleoside reverse transcriptase inhibitor regimens in HIV-1 infected naive patients. Aids. 2009; 23(7):817–24. https://doi.org/10.1097/QAD.0b013e32832df689 PMID: 19363330

20. Grant PM, Cotter AG. Tenofovir and bone health. Current opinion in HIV and AIDS. 2016; 11(3):326–32. https://doi.org/10.1097/COH.0000000000000248 PMID: 26859637

21. World Health Organization. Updated recommendations on first-line and second-line antiretroviral regimens and post-exposure prophylaxis and recommendations on early infant diagnosis of HIV: interim guidelines: supplement to the 2016 consolidated guidelines on the use of antiretroviral drugs for treating and preventing HIV infection: World Health Organization; 2018.

22. Brown TT, McComsey GA, King MS, Qaqish RB, Bernstein BM, da Silva BA. Loss of bone mineral density after antiretroviral therapy initiation, independent of antiretroviral regimen. J Acquir Immune Defic Syndr. 2009; 51(5):554–61. https://doi.org/10.1097/QAI.0b013e3181adce44 PMID: 19512937

23. Grant PM, Kitch D, McComsey GA, Collier AC, Koletar SL, Erlandson KM, et al. Long-term Bone Mineral Density Changes in Antiretroviral-Treated HIV-Infected Individuals. The Journal of Infectious Diseases. 2018; 214(4):607–11. https://doi.org/10.1093/infdis/jiw204 PMID: 27930053

24. Walton RJ, Bijvoet OL. Nomogram for derivation of renal threshold phosphate concentration. Lancet. 1975; 2(7929):309–10. https://doi.org/10.1016/s0140-6736(75)92736-1 PMID: 50513

25. Lucas GM, Ross MJ, Stock PG, Shlipak MG, Wyatt CM, Gupta SK, et al. Clinical Practice Guideline for the Management of Chronic Kidney Disease in Patients Infected With HIV: 2014 Update by the HIV Medicine Association of the Infectious Diseases Society of America. Clinical Infectious Diseases. 2014; 59(9):e96–e138. https://doi.org/10.1093/cid/ciu617 PMID: 25234519

26. Kanis JA, Melton LJ 3rd, Christiansen C, Johnston CC, Khaltava N. The diagnosis of osteoporosis. Journal of bone and mineral research: the official journal of the American Society for Bone and Mineral Research. 1994; 9(8):1137–41.

27. McComsey GA, Kitch D, Daar ES, Tierney C, Jahed NC, Tebas P, et al. Bone mineral density and fractures in antiretroviral-naive persons randomized to receive abacavir-lamivudine or tenofovir disoproxil fumarate-emtricitabine along with efavirenz or atazanavir-ritonavir: Aids Clinical Trials Group A5224s, a substudy of ACTG A5202. J Infect Dis. 2011; 203(12):1791–801. https://doi.org/10.1093/infdis/jir188 PMID: 21606537

28. Sax PE, Wohl D, Yin MT, Post F, DeJesus E, Saag M, et al. Tenofovir alafenamide versus tenofovir disoproxil fumarate, coformulated with elvitegravir, cobicistat, and emtricitabine, for initial treatment of HIV-1 infection: two randomised, double-blind, phase 3, non-inferiority trials. Lancet. 2015; 385(9987):2606–15. https://doi.org/10.1016/S0140-6736(15)60616-X PMID: 25890673

29. Gallant JE, Staszewski S, Pozniak AL, DeJesus E, Suleiman JM, Miller MD, et al. Efficacy and safety of tenofovir DF vs stavudine in combination therapy in antiretroviral-naive patients: a 3-year randomized trial. Jama. 2004; 292(2):191–201. https://doi.org/10.1001/jama.292.2.191 PMID: 15249568
30. Bernardino JL, Mocroft A, Mallon PW, Wallet C, Gerstoft J, Russell C, et al. Bone mineral density and inflammatory and bone biomarkers after darunavir-ritonavir combined with either raltegravir or tenofovir-emtricitabine in antiretroviral-naive adults with HIV-1: a substudy of the NEAT001/ANRS143 randomised trial. Lancet HIV. 2015; 2(11):e464–73. https://doi.org/10.1016/S2352-3018(15)00181-2 PMID: 26520926

31. Mills A, Crofoot G Jr., McDonald C, Shalit P, Flamm JA, Gathe J Jr., et al. Tenofovir Alafenamide Versus Tenofovir Disoproxil Fumarate in the First Protease Inhibitor-Based Single-Tablet Regimen for Initial HIV-1 Therapy: A Randomized Phase 2 Study. J Acquir Immune Defic Syndr. 2015; 69(4):439–45. https://doi.org/10.1097/QAI.00000000000000618 PMID: 25867913

32. Erlandson KM, Kitch D, Tierney C, Sax PE, Daar ES, Tebas P, et al. Weight and lean body mass change with antiretroviral initiation and impact on bone mineral density. AIDS. 2013; 27(13):2069–79. https://doi.org/10.1097/QAD.0b013e328361d25d PMID: 24384588

33. Todd T Brown MTY, Samir Gupta, Christine Katlama, Adriano Lazzarin, Kathy Melbourne, Calvin Cohen, et al. Switching from TDF to TAF in HIV-Infected Adults With Low BMD: A Pooled Analysis. Conference on Retroviruses and Opportunistic Infections (CROI),; February 13–16, 2017; Seattle, WA2017.